findmyKOL
Clinical trialNCT01394939CompletedPhase 1/PHASE2Interventional

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

SponsorJennerex BiotherapeuticsEnrollment52CRCColorectal Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of JX-594 (Pexa-Vec) administered intravenously either alone or in combination with Irinotecan in colorectal carcinoma patients who are refractory to or intolerant to standard therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • Ottawa Hospital and Research Institute (ohri)

    Ottawa, Ontario, Canada

France
  • Hôpital Saint Antoine

    Paris, France

  • Hôpital Hautepierre

    Strasbourg, France

  • Institut Claudius Regaud

    Toulouse, France

United States
  • Mayo Clinic

    Scottsdale, Arizona, United States

  • Ucsd Moores Cancer Center

    La Jolla, California, United States

  • Billings Clinic Cancer Center

    Billings, Montana, United States

  • University of North Carolina

    Chapel Hill, North Carolina, United States

  • Gabrail Cancer Center

    Canton, Ohio, United States

  • the Ohio State University

    Columbus, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Irinotecan →JX-594
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2012
Primary completion
30 Jun 2015
Completion
31 Oct 2015
Last update posted
5 Aug 2026
Registered enrollment
52
Registry id
NCT01394939
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.